Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,742 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Multiple-dose pharmacokinetics, pharmacodynamics, and safety of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, in healthy male volunteers.
Addy C, Rothenberg P, Li S, Majumdar A, Agrawal N, Li H, Zhong L, Yuan J, Maes A, Dunbar S, Cote J, Rosko K, Van Dyck K, De Lepeleire I, de Hoon J, Van Hecken A, Depré M, Knops A, Gottesdiener K, Stoch A, Wagner J. Addy C, et al. Among authors: agrawal n. J Clin Pharmacol. 2008 Jun;48(6):734-44. doi: 10.1177/0091270008317591. J Clin Pharmacol. 2008. PMID: 18508950 Clinical Trial.
Characterization of etoricoxib, a novel, selective COX-2 inhibitor.
Dallob A, Hawkey CJ, Greenberg H, Wight N, De Schepper P, Waldman S, Wong P, DeTora L, Gertz B, Agrawal N, Wagner J, Gottesdiener K. Dallob A, et al. Among authors: agrawal n. J Clin Pharmacol. 2003 Jun;43(6):573-85. J Clin Pharmacol. 2003. PMID: 12817520 Clinical Trial.
Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, for the treatment of obesity: results from a double-blind, placebo-controlled, single oral dose study in healthy volunteers.
Addy C, Li S, Agrawal N, Stone J, Majumdar A, Zhong L, Li H, Yuan J, Maes A, Rothenberg P, Cote J, Rosko K, Cummings C, Warrington S, Boyce M, Gottesdiener K, Stoch A, Wagner J. Addy C, et al. Among authors: agrawal n. J Clin Pharmacol. 2008 Apr;48(4):418-27. doi: 10.1177/0091270008314467. Epub 2008 Feb 7. J Clin Pharmacol. 2008. PMID: 18258750 Clinical Trial.
Pharmacokinetics of etoricoxib in patients with hepatic impairment.
Agrawal NG, Rose MJ, Matthews CZ, Woolf EJ, Porras AG, Geer LA, Larson PJ, Cote J, Dilzer SC, Lasseter KC, Alam I, Petty KJ, Gottesdiener KM. Agrawal NG, et al. J Clin Pharmacol. 2003 Oct;43(10):1136-48. doi: 10.1177/0091270003257219. J Clin Pharmacol. 2003. PMID: 14517196 Clinical Trial.
Pharmacokinetics of etoricoxib in patients with renal impairment.
Agrawal NG, Matthews CZ, Mazenko RS, Kline WF, Woolf EJ, Porras AG, Geer LA, Wong PH, Cho M, Cote J, Marbury TC, Moncrief JW, Alcorn H Jr, Swan S, Sack MR, Robson RA, Petty KJ, Schwartz JI, Gottesdiener KM. Agrawal NG, et al. J Clin Pharmacol. 2004 Jan;44(1):48-58. doi: 10.1177/0091270003260338. J Clin Pharmacol. 2004. PMID: 14681341
The effects of modifying in vivo cytochrome P450 3A (CYP3A) activity on etoricoxib pharmacokinetics and of etoricoxib administration on CYP3A activity.
Agrawal NG, Matthews CZ, Mazenko RS, Woolf EJ, Porras AG, Chen X, Miller JL, Michiels N, Wehling M, Schultz A, Gottlieb AB, Kraft WK, Greenberg HE, Waldman SA, Curtis SP, Gottesdiener KM. Agrawal NG, et al. J Clin Pharmacol. 2004 Oct;44(10):1125-31. doi: 10.1177/0091270004268129. J Clin Pharmacol. 2004. PMID: 15342613 Clinical Trial.
1,742 results